Kuks, P.F.

patient hiv-infected atovaquone /ritonavir hiv-infected patients lopinavir /ritonavir study pneumococcal cancer vaccine group serotype virus atazanavir /ritonavir lopinavir incidence atazanavir vaccination concentration antibody disease response efavirenz proguanil population hospital lung cancer /proguanil antiretroviral hiv infection plasma women speci fic antibodies france lopinavir / ritonavir 8 weeks hiv-infected adults haart bower m 1 mg /ml fidence interval atazanavir / ritonavir adult william centre polysaccharide count volunteer infection nijmegen lippincott wilkin department infarction cohort conjugate sample reproduction article research avidity speci university risk factors copyright atovaquone plasma concentrations radboud university nijmegen ritonavir 200 cells /ml medicine increase merkel polysaccharide pneumococcal vaccine merkel cell polyomavirus ratio non-aids-de fining cancers interval effect mechanism pneumococcal vaccine